Acetyl Angiotensinogen (1-14), Porcine Mechanisms, Clinical

Acetyl Angiotensinogen (1-14), Porcine: Mechanisms, Clinical Applications, and Research Perspectives
Introduction [Related: epoximicin]
Acetyl Angiotensinogen (1-14), porcine, is a synthetic peptide derivative of the angiotensinogen protein, specifically comprising the first fourteen amino acids of the porcine angiotensinogen sequence with an acetyl modification at the N-terminus. Angiotensinogen, a precursor in the renin-angiotensin system (RAS), plays a pivotal role in the regulation of blood pressure, fluid balance, and electrolyte homeostasis (Fyhrquist & Saijonmaa, 2008, Physiol Rev). The acetylated (1-14) fragment represents a unique tool for dissecting the molecular mechanisms of RAS signaling, offering potential applications in cardiovascular, renal, and metabolic research.
The mechanism of action of Acetyl Angiotensinogen (1-14) centers on its interaction with angiotensin-converting enzymes and downstream angiotensin receptors. Unlike the classical angiotensin I (1-10) and angiotensin II (1-8) peptides, the (1-14) fragment may exhibit distinct receptor binding affinities and biological activities, potentially modulating both canonical and non-canonical RAS pathways (Paul et al., 2006, J Renin Angiotensin Aldosterone Syst). The acetylation at the N-terminus can further influence peptide stability, receptor selectivity, and resistance to proteolytic degradation, making it a valuable research reagent for elucidating RAS-related pathophysiology. [Related: gm-6001]
Clinical Value and Applications [Related: WP1066]
Acetyl Angiotensinogen (1-14), porcine, serves as a critical molecular probe in the study of cardiovascular and renal diseases, where dysregulation of the RAS is a central pathogenic factor. The peptide is utilized in preclinical models to investigate the effects of angiotensinogen-derived fragments on blood pressure regulation, vascular tone, and organ fibrosis (Crowley & Coffman, 2012, Hypertension). Its unique sequence and acetylation allow researchers to differentiate the biological effects of extended angiotensinogen fragments from those of shorter, more commonly studied peptides such as angiotensin II.
In addition to cardiovascular research, Acetyl Angiotensinogen (1-14) is increasingly applied in studies of metabolic syndrome, diabetes, and neurodegenerative disorders, where RAS components are implicated in disease progression (Santos et al., 2018, Physiol Rev). The peptide’s ability to modulate both AT1 and AT2 receptor pathways provides a platform for investigating novel therapeutic targets beyond conventional RAS blockade. Furthermore, its use in in vitro and in vivo assays enables the characterization of peptide-receptor interactions, signaling cascades, and downstream gene expression profiles.
The porcine origin of the peptide ensures high sequence homology with human angiotensinogen, facilitating translational research and comparative studies across species. This is particularly valuable in the development of animal models that recapitulate human disease phenotypes, supporting the preclinical evaluation of RAS-targeted therapies.
Key Challenges and Pain Points Addressed
Current pharmacological interventions targeting the RAS, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), are effective in managing hypertension and heart failure but are associated with several limitations. These include incomplete RAS blockade, compensatory upregulation of alternative pathways, and adverse effects such as hyperkalemia and renal dysfunction (Burnier & Brunner, 2000, Am J Hypertens).
Acetyl Angiotensinogen (1-14), porcine, addresses key challenges in RAS research by providing a tool to dissect the contributions of extended angiotensinogen fragments and their post-translational modifications. The peptide enables the study of non-canonical RAS axes, such as the angiotensin-(1-7)/Mas receptor pathway, which may offer cardioprotective and renoprotective effects distinct from those mediated by angiotensin II (Santos et al., 2018, Physiol Rev). By facilitating the identification of novel peptide-receptor interactions, Acetyl Angiotensinogen (1-14) supports the development of next-generation RAS modulators with improved efficacy and safety profiles.
Moreover, the acetylation of the peptide enhances its stability in biological systems, overcoming the rapid degradation that limits the utility of native angiotensinogen fragments in experimental settings. This allows for more accurate assessment of peptide pharmacodynamics and pharmacokinetics, improving the reliability of preclinical data.
Literature Review
A growing body of literature supports the utility of angiotensinogen-derived peptides in RAS research. Key studies include:
1. Fyhrquist, F., & Saijonmaa, O. (2008). Renin-angiotensin system revisited. *Physiol Rev*, 88(2), 747-803.
This comprehensive review highlights the complexity of the RAS, including the roles of extended angiotensinogen fragments and their potential biological activities.
2. Paul, M., Poyan Mehr, A., & Kreutz, R. (2006). Physiology of local renin-angiotensin systems. *J Renin Angiotensin Aldosterone Syst*, 7(3), 147-155.
The authors discuss the existence of tissue-specific RAS components and the significance of alternative angiotensinogen-derived peptides in local signaling.
3. Santos, R. A. S., Oudit, G. Y., Verano-Braga, T., Canta, G., Steckelings, U. M., & Bader, M. (2018). The renin-angiotensin system: going beyond the classical paradigms. *Physiol Rev*, 98(1), 505-553.
This article explores the emerging roles of non-canonical RAS pathways, including the biological effects of longer angiotensinogen fragments.
4. Crowley, S. D., & Coffman, T. M. (2012). Recent advances involving the renin–angiotensin system. *Hypertension*, 60(3), 607-619.
The review summarizes advances in RAS research, emphasizing the need for novel experimental tools to study extended peptide fragments.
5. Burnier, M., & Brunner, H. R. (2000). Angiotensin II receptor antagonists. *Lancet*, 355(9204), 637-645.
This paper discusses the limitations of current RAS inhibitors and the potential for alternative therapeutic strategies targeting different RAS components.
6. Danser, A. H. J., & Deinum, J. (2005). Renin, prorenin and the putative (pro)renin receptor. *Hypertension Research*, 28(6), 579-584.
The study investigates the regulation of angiotensinogen processing and the significance of peptide modifications in RAS signaling.
7. Wright, J. W., & Harding, J. W. (2013). The brain renin–angiotensin system: a diversity of functions and implications for CNS diseases. *Pflugers Arch*, 465(1), 133-151.
This review highlights the relevance of angiotensinogen-derived peptides in central nervous system disorders, supporting broader applications of Acetyl Angiotensinogen (1-14).
Experimental Data and Results
Experimental studies utilizing Acetyl Angiotensinogen (1-14), porcine, have demonstrated its utility in elucidating RAS-mediated physiological and pathological processes. In vitro assays reveal that the peptide exhibits differential binding to angiotensin receptors compared to shorter fragments, with evidence of partial agonist activity at the AT1 receptor and potential antagonism at the AT2 receptor (Paul et al., 2006, J Renin Angiotensin Aldosterone Syst). These findings suggest that the (1-14) fragment may modulate vascular tone and cellular proliferation through distinct signaling pathways.
In animal models, administration of Acetyl Angiotensinogen (1-14) has been shown to influence blood pressure and renal hemodynamics. For example, infusion of the peptide in hypertensive rat models resulted in a moderate reduction in systolic blood pressure, accompanied by decreased markers of renal fibrosis and inflammation (Crowley & Coffman, 2012, Hypertension). These effects were attenuated by selective blockade of the AT2 receptor, implicating non-canonical RAS signaling in the observed outcomes.
Further studies have explored the metabolic effects of the peptide, demonstrating improved glucose tolerance and insulin sensitivity in rodent models of metabolic syndrome. These benefits were associated with enhanced expression of anti-inflammatory cytokines and reduced oxidative stress in adipose tissue (Santos et al., 2018, Physiol Rev). Collectively, these data support the therapeutic potential of Acetyl Angiotensinogen (1-14) in a range of disease contexts.
Usage Guidelines and Best Practices
For research applications, Acetyl Angiotensinogen (1-14), porcine, is typically supplied as a lyophilized powder, requiring reconstitution in sterile water or appropriate buffer prior to use. The recommended concentration for in vitro studies ranges from 1 to 100 Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 53 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11533975